336 related articles for article (PubMed ID: 18613218)
1. Plasma glycooxidation protein products in type 2 diabetic patients with nephropathy.
Piwowar A; Knapik-Kordecka M; Szczecińska J; Warwas M
Diabetes Metab Res Rev; 2008 Oct; 24(7):549-53. PubMed ID: 18613218
[TBL] [Abstract][Full Text] [Related]
2. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H
Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
[TBL] [Abstract][Full Text] [Related]
3. Association of haptoglobin phenotypes with markers of diabetic nephropathy in Type 2 diabetes mellitus.
Awadallah SM; Saleh SA; Abu Shaqra QM; Hilow H
J Diabetes Complications; 2008; 22(6):384-8. PubMed ID: 18413152
[TBL] [Abstract][Full Text] [Related]
4. [Advanced oxidation protein products in diabetic nephropathy patients and its relation with superoxide dismutase, glutathione peroxidase, neopterin].
Wu ZX; Xue YM; Li CZ; Guan MP
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 30(6):704-7. PubMed ID: 16708815
[TBL] [Abstract][Full Text] [Related]
5. [Oxidative stress and endothelium dysfunction in diabetes mellitus type 2].
Piwowar A; Knapik-Kordecka M; Warwas M
Pol Merkur Lekarski; 2008 Aug; 25(146):120-3. PubMed ID: 18942329
[TBL] [Abstract][Full Text] [Related]
6. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus.
Kim NH; Kim KB; Kim DL; Kim SG; Choi KM; Baik SH; Choi DS; Kang YS; Han SY; Han KH; Ji YH; Cha DR
Diabet Med; 2004 Jun; 21(6):545-51. PubMed ID: 15154937
[TBL] [Abstract][Full Text] [Related]
7. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
[TBL] [Abstract][Full Text] [Related]
8. [The total antioxidant capacity and low-molecular antioxidant concentration in plasma of type-2 diabetes patients with different stage of metabolic compensation and concomitant diabetic nephropathy].
Błaszczak R; Kujawski K; Kedziora-Kornatowska K; Kornatowski T; Kedziora J; Szadujkis-Szadurski L; Markuszewski L; Rysz J; Ertel D; Olszewski R
Pol Merkur Lekarski; 2005 Jan; 18(103):29-32. PubMed ID: 15859542
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the usefulness of plasma levels of oxidatively modified forms of albumin in estimating kidney dysfunction in diabetic patients.
Piwowar A; Knapik-Kordecka M; Warwas M
Clin Invest Med; 2010 Apr; 33(2):E109. PubMed ID: 20370990
[TBL] [Abstract][Full Text] [Related]
10. The association of advanced glycation end-products with glutathione status.
Sahin E; Göçmen AY; Koçak H; Tuncer M; Gümüslü S
Ann Clin Biochem; 2008 Jul; 45(Pt 4):369-74. PubMed ID: 18583621
[TBL] [Abstract][Full Text] [Related]
11. Elevation of urinary betaig-h3, transforming growth factor-beta-induced protein in patients with type 2 diabetes and nephropathy.
Ha SW; Kim HJ; Bae JS; Jeong GH; Chung SC; Kim JG; Park SH; Kim YL; Kam S; Kim IS; Kim BW
Diabetes Res Clin Pract; 2004 Aug; 65(2):167-73. PubMed ID: 15223229
[TBL] [Abstract][Full Text] [Related]
12. Does renal function influence plasma levels of advanced glycation and oxidation protein products in patients with chronic rheumatic diseases complicated by secondary amyloidosis?
Rysavá R; Kalousová M; Zima T; Dostál C; Merta M; Tesar V
Kidney Blood Press Res; 2007; 30(1):1-7. PubMed ID: 17191033
[TBL] [Abstract][Full Text] [Related]
13. Serum and urinary type IV collagen concentrations in the assessment of diabetic microangiopathy.
Banu N; Hara H; Egusa G; Yamakido M
Hiroshima J Med Sci; 1994 Dec; 43(4):123-33. PubMed ID: 7883578
[TBL] [Abstract][Full Text] [Related]
14. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.
Sebeková K; Gazdíková K; Syrová D; Blazícek P; Schinzel R; Heidland A; Spustová V; Dzúrik R
J Hum Hypertens; 2003 Apr; 17(4):265-70. PubMed ID: 12692571
[TBL] [Abstract][Full Text] [Related]
15. [Oxidative-antioxidative balance disturbance and risk factors as well as vascular complications in patients with diabetes type 2].
Knapik-Kordecka M; Piwowar A; Warwas M
Wiad Lek; 2007; 60(7-8):329-34. PubMed ID: 18175551
[TBL] [Abstract][Full Text] [Related]
16. Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors.
Valli A; Suliman ME; Meert N; Vanholder R; Lindholm B; Stenvinkel P; Watanabe M; Barany P; Alvestrand A; Anderstam B
Clin Chim Acta; 2007 Apr; 379(1-2):87-94. PubMed ID: 17292872
[TBL] [Abstract][Full Text] [Related]
17. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes.
Saraheimo M; Forsblom C; Thorn L; Wadén J; Rosengård-Bärlund M; Heikkilä O; Hietala K; Gordin D; Frystyk J; Flyvbjerg A; Groop PH;
Diabetes Care; 2008 Jun; 31(6):1165-9. PubMed ID: 18346990
[TBL] [Abstract][Full Text] [Related]
18. Markers of oxidative protein damage in plasma and urine of type 2 diabetic patients.
Piwowar A; Knapik-Kordecka M; Warwas M
Br J Biomed Sci; 2009; 66(4):194-9. PubMed ID: 20095128
[TBL] [Abstract][Full Text] [Related]
19. Elevated plasma atrial natriuretic peptide level in the early phase of microalbuminuria in patients with non-insulin-dependent diabetes mellitus.
Shinoda T; Ishihara M; Kurimoto F; Aizawa T; Hiramatsu K; Shirota T; Takasu N; Yamada T
Clin Nephrol; 1990 Nov; 34(5):202-7. PubMed ID: 2148510
[TBL] [Abstract][Full Text] [Related]
20. [Changes in serum and urine ceruloplasmin concentrations in type 2 diabetes].
Qin LX; Zeng X; Huang G
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 29(2):208-11. PubMed ID: 16145917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
